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Many single nucleotide variants (SNVs) associated with human traits and genetic diseases
are thought to alter the activity of existing regulatory elements. Some SNVs may also create
entirely new regulatory elements which change gene expression, but the mechanism by
which they do so is largely unknown. Here we show that a single base change in an otherwise
unremarkable region of the human α-globin cluster creates an entirely new promoter and an
associated unidirectional transcript. This SNV downregulates α-globin expression causing
α-thalassaemia. Of note, the new promoter lying between the α-globin genes and their
associated super-enhancer disrupts their interaction in an orientation-dependent manner.
Together these observations show how both the order and orientation of the fundamental
elements of the genome determine patterns of gene expression and support the concept that
active genes may act to disrupt enhancer-promoter interactions in mammals as in Droso-
phila. Finally, these findings should prompt others to fully evaluate SNVs lying outside of
known regulatory elements as causing changes in gene expression by creating new regulatory
elements.
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A large proportion of the single nucleotide variants (SNVs)associated with human traits and predisposition to humandisease lie within non-coding regions of the genome1.
Therefore, the causative variants are presumed to affect the
fundamental regulatory elements of the genome including
enhancers, promoters and boundary elements2,3. We previously
described the emergence of a new transcriptional unit in a non-
regulatory region of the α-globin locus which causes down-
regulation of α-globin expression (α-thalassaemia) in individuals
from Melanesia. In the same study we identified a candidate for
the causal mutation: a single nucleotide (T to C) change which
resulted in a new binding site for the erythroid master regulator
GATA-1 and the production of a new RNA transcript4. This
provides an example of a trait associated SNV that appears to
create a new regulatory element rather than disrupting an existing
element. Few “gain-of-function” SNVs have been identified4–7
and as yet the prevalence and full repertoire of mechanisms by
which such SNVs might alter gene expression have not yet been
determined.
The candidate SNV (a T to C transition at coordinate hg19
chr16:209,709) which is thought to down regulate α-globin
expression is found within an unremarkable non-coding region of
the α-globin locus. This multi gene cluster lies within a relatively
small, well characterised topologically associated sub-domain (a
sub-TAD of ~80 kb) flanked by CTCF-boundary elements within
the telomeric region of chromosome 168–11. The sub-TAD
includes embryonic (ζ - HBZ), fetal/adult (α–HBA1/2) and theta
(θ–HBQ) globin genes which are regulated by four enhancers (R1,
R2, R3 and R4) arranged in the order 5′-R1-R2-R3-R4-ζ-α2-α1-
θ1-3′. The locus is only active in erythroid cells where active
regulatory regions are found in open chromatin associated with
acetylated lysine at position 27 of histone H3 (H3K27ac).
Enhancers are marked by monomethyl lysine 4 of histone H3
(H3K4me1) and promoters by trimethyl lysine 4 of histone H3
(H3K4me3). Although we have previously shown that the
emergence of a new site of transcriptional activity is associated
with downregulation of α-globin expression4, whether the T to C
change is causative and the mechanism by which this disrupts
normal regulation is not yet clear.
Here we demonstrate that a point mutation in a non-regulatory
region of the human α-globin locus can establish a promoter
element that is capable of affecting the expression of nearby native
genes. We show that that activity of the novel element cannot
be easily explained by a competition model since it disrupts the
native promoter-enhancer interactions in an orientation-
dependent manner. Our observations underline the link between
the order and orientation of the fundamental elements of the
genome and highlight the complexity of gene regulation.
Results
Point mutation creates new promoter that downregulates
native genes. To investigate the SNV created by the T-C transi-
tion we generated induced pluripotent stem cell (iPSC) lines from
cells that carry the C allele (C-SNV) at position 209,709 (hg19) on
both copies of chromosome 16 (Supplementary Fig. 1a, b). The
iPSC lines were differentiated down the erythroid pathway
(Supplementary Fig. 1c)12. To characterise the new transcrip-
tional unit we analysed chromatin accessibility (ATAC-seq), the
epigenetic landscape (ChIP-seq) and transcription profile (RNA-
seq) of the α-globin locus. In the mutant cells (C-SNV) there is a
new region of open chromatin associated with the site of the
candidate (T-C) mutation (Fig. 1A). This newly formed accessible
site is bound by RNA polymerase II (RNAP II) and is marked by
prominent peaks of H3K27ac and H3K4me3 while the difference
in H3K4me1 between the wild type and the mutant C-SNV cells
is far less pronounced (Fig. 1B). This chromatin signature is
consistent with that observed at most active promoters13–16.
Strand specific RNA-seq demonstrates that the C-SNV promoter
produces both non-polyadenylated (pA-) and polyadenylated
(pA+) transcripts, but only in the sense direction with respect to
the published human genome (Fig. 1C). Thus, transcription is
directed away from the enhancers, in the same direction as
transcription of the α-globin genes. To determine if the mutant
cells have reduced levels of α-globin mRNA, as seen in individuals
carrying this mutation, we performed qPCR analysis on three
mutant C-SNV iPSC clones and three independently generated
normal human iPSC lines (WT) differentiated to erythroblasts.
There was a roughly two-fold reduction in α-globin mRNA in the
C-SNV erythroid cells compared to the wild type lines (Fig. 1D).
These findings show that the iPSC system recapitulates the phe-
notype observed in erythroid cells from individuals carrying the
C-SNV.
To understand how the local DNA sequence might facilitate
the establishment of the novel C-SNV promoter we studied the
site at the 5’ end of the transcribed region. We mapped the
transcription start site (TSS) using RLM-RACE and identified the
most likely transcription initiation element to be the core
promoter element XCPE117 (Supplementary Fig. 2). The T-C
variant generates a recognition motif for the erythroid transcrip-
tion factor (TF) GATA1 and this particular GATA1 site is part of
a wider half E-box-GATA motif, commonly co-occupied by
TAL118–20. Correspondingly the site of the mutation is bound
both by GATA1 and TAL1 in primary erythroblasts homozygous
for the mutation21. In addition, we identified a strong binding
motif for another key erythroid TF KLF1, in the immediate
vicinity of the GATA1 motif (Fig. 2A). Using ChIP-seq we found
a near two-fold increase in GATA1 occupancy and over four-fold
increase in KLF1 binding in the vicinity of the C-SNV (Fig. 2B).
This is of interest since both GATA1 and KLF1 are master
regulators of erythroid genes22–25, have a role in establishing and/
or maintaining chromatin conformation26–29, and are often
found to co-occupy the same sites in erythroid cells30. Of interest,
we analysed the predicted chromatin accessibility of the human
α-globin gene cluster with and without the candidate SNV using a
recently established, convoluted neural network (DeepHaem)
[https://github.com/rschwess/deepHaem]. DeepHaem has pre-
viously been used to predict chromatin accessibility and its effect
on higher order chromatin structures using DeepC31. This
network predicts that the C-SNV mutation alone is sufficient to
create an open chromatin site whose accessibility increases as cells
differentiate along the erythroid pathway (Supplementary
Fig. 2b).
To determine experimentally whether the T to C transition is
the sole causative variant we introduced this point mutation
homozygously into wild type cells and reverted the mutation in
mutant cells (for genetic screening and quality control see
Supplementary Fig. 2). Editing the mutant C allele to a T (C–T
lines) abolished the accessible chromatin site surrounding the
mutation and transcription at the site of the SNV became
undetectable (Fig. 2C–E). Conversely, introducing the mutant C
allele in wild type cells (T–C lines) produces a region of accessible
chromatin at the site of the SNV and transcription of this region
(Fig. 2C–E). We performed qPCR to determine if the T to C
transition causes downregulation of α-globin. The C–T lines
showed an over two-fold increase in α-globin mRNA when
compared to its isogenic control C-SNV line. Conversely, the T–C
lines showed over 55% reduction in α-globin transcript (Fig. 2D).
These results prove that the T to C transition is both necessary
and sufficient to cause the observed phenotype and that the
accumulation of erythroid TFs around the TSS is causative rather
than corelative in creating a new promoter element.
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The new promoter sequesters enhancers away from native
promoters. The emergence of a new promoter, induced by key
erythroid transcription factors like GATA1, in an erythroid-
specific locus suggests that its expression may be regulated by the
local enhancers. Indeed, GATA1 is thought to promote chro-
matin looping through its binding partners, among those that
have shown to play a role in chromatin conformation are the co-
factor FOG132–34 and the multimeric LDB1-complex. The LDB1-
complex consists of TAL1/E-protein heterodimer bound to
GATA1 via LMO2 and LDB135 and is thought to achieve tran-
scriptional regulation through facilitating interactions between
distal regulatory elements and promoters23,36,37. Genome wide
studies have identified frequently occurring composite TAL1 and
GATA1 binding sites known as Ebox-GATA1 motifs at erythroid
regulatory elements38 confirming their co-association. In addi-
tion, GATA1 has been shown to cooperate with the TF NF-E2 to
contribute to the recruitment of the ATPase component of SWI/
SNF chromatin remodelling complex–BRG1, in order to facilitate
the formation of accessible chromatin38 and to maintain higher
order chromatin structure27,29. In particular, BRG1 is required for
long range interactions in the mouse α-globin locus39 where
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on during erythroid differentiation40. To test if the C-SNV ele-
ment comes into close proximity with the α-globin enhancers, we
assessed the interaction between key sites in the α-globin locus
using Capture-C41. Analysis of the interaction profiles of C-SNV
erythroid cells and wild type cells, from the viewpoint of the new
promoter, shows an increase in mean interaction frequency
between the α-globin enhancers and the new promoter (Fig. 3A).
To determine if this interaction occurs at the expense of contacts
between the α-globin enhancers and their cognate promoters we
performed Capture-C from the viewpoint of the promoters of the
α-globin genes (HBA1 and HBA2). This showed a marked
decrease in mean interaction frequency between the α-globin
promoters and enhancers in the presence of the new C-SNV
promoter (Fig. 3B). To confirm that this observation holds true
from the point of view of the α-globin enhancers we also per-
formed Capture-C from the R2 enhancer (Fig. 3C). This
demonstrates that in erythroid cells homozygous for the C allele,
the α-globin enhancers display a higher mean interaction fre-
quency over the region of the active C-SNV promoter and a
reduction of interactions with the α-globin promoters, and that
this is likely to be an important component underlying the
reduction in α-globin expression.
Reduced contacts between the enhancers and the α-globin
promoters in the presence of the newly formed promoter could be
explained by a model of mutually exclusive promoter competi-
tion, which has previously been proposed to explain several forms
of complex gene regulation42,43. Alternatively, this could be
explained by the formation of an insulator element by the new
promoter, reminiscent of that observed at a subset of Drosophila
promoters which act as enhancer blockers; a type of insulator
element that restricts enhancer–promoter interactions44. Struc-
tural boundary elements that regulate chromatin architecture are
commonly associated with the presence of the CCCTC-binding
factor (CTCF)45,46. A CTFC ChIP-seq analysis showed that there
are no new CTCF peaks that appear in the C-SNV lines,
demonstrating that the activity of the C-SNV promoter alone is
the cause of the shift in chromatin interactions (Fig. 3D).
The competition model cannot explain the full effect of the
new promoter. We next wanted to understand whether the effect
of the C-SNV promoter was due to mutually exclusive promoter
competition which should result in the promoter exerting its
effect on chromatin interactions and gene expression irrespective
of its position in the sub-TAD. Alternatively, if the C-SNV
promoter is acting as an enhancer blocker its location (and per-
haps orientation) relative to the native promoters and enhancers
in the locus would determine its effect on gene regulation. To test
the competition model, we placed the sequence of the active C-
SNV promoter upstream of the α-globin enhancers in a wild type
line, in the antisense orientation, directed away from the
enhancers (Fig. 4A) (for genome editing design and genetic
screen see Supplementary Fig. 3). Importantly, this insertion still
lies within the α-globin sub-TAD and therefore should be equally
accessible to the enhancers. In addition, the ectopically placed C-
SNV promoter lies closer to the major R2 enhancer (14 kb) than
the α-globin genes (59 kb) or the original position of the C-SNV
(46 kb). ATAC-seq showed that the transposed C-SNV promoter
sequence opens chromatin in this new position (Fig. 4B). The
associated chromatin showed a large increase in H3K27ac and
H3K4me3, and a less pronounced increase in H3K4me1 (Fig. 4C)
together with unidirectional transcription originating at the TSS
of the transposed C-SNV promoter (Fig. 4D). This transcript
extends away from the enhancers on what is now the antisense
strand of DNA. Thus, when placed within the sub-TAD upstream
of the enhancers, the C-SNV sequence can still act as a bona fide
promoter. Interestingly, when the promoter was placed in the
sense orientation, it again created a region of open chromatin
marked by H3K27ac and H3K4me1 but not by H3K4me3. In this
case there were no detectable RNA transcripts (Supplementary
Fig. 4). Together, these observations suggest that the orientation
of this promoter relative to other elements may determine whe-
ther or not it is recognised as a promoter.
To test if the transposed transcriptionally active C-SNV
promoter affected α-globin expression, we performed qPCR
analysis. There was a reduction (25.6%, p= 0.0322) in mean
α-globin transcript levels seen between cells where the tran-
scriptionally active C-SNV promoter is placed upstream of the
α-globin enhancers and wild type cells. However, we observed a
larger reduction (55.7%, p= 0.0005) in cells of the same genomic
background in which the C-SNV promoter is in its original
position between the enhancers and α-globin promoters (T-C)
(Fig. 4E). This is not sufficient to explain the severity of the
phenotype that the C-SNV promoter produces in its native
location. To determine if the transposed C-SNV promoter exerts
any effect on chromatin interactions in the α-globin locus when
placed upstream of the enhancers we performed Capture-C from
enhancer R2 and the promoters of HBA1 and HBA2. This showed
no major change in chromatin interactions between the α-globin
promoters and their enhancers in line with the minor change in
Fig. 1 New transcriptional unit bears the marks of a unidirectional promoter and causes α-globin downregulation. A Chromatin accessibility in the α-
globin locus as measured by ATAC-seq. The enhancer elements (R1–R4) are highlighted in orange, the site of the T to C mutation is highlighted in green
(labelled SNV for single nucleotide variant), gene annotation by Refseq is in blue. Read-densities represent an average of 3 independent differentiation
experiments, 3 independent wild type iPSC lines (labelled WT) or 3 iPSC clones obtained from the same patient material homozygous for the C allele of the
SNV located at coordinate (hg19) chr16:209,709 (labelled C-SNV), differentiated to erythroblasts. Coordinates (hg19) chr16:108,000-238,000. B ChIP-
seq, highlighted regions are as in A. Read-densities represent an average of 3 independent experiments, 3 replicates for wild type iPSC line AH017-13 (in
blue) or 3 C-SNV iPSC clones obtained from the same patient material (in red) differentiated to erythroblasts. The tracks are overplayed on top of each
other, black indicates shared signal while red and blue indicate signal unique for the mutant and wild type lines, respectively. Coordinates (hg19)
chr16:108,000-238,000. The level of the signal in the middle of the C-SNV transcriptional unit is most likely affected by the presence of a variable number
tandem repeat (inter-ζ VNTR), a 1 kb sequence in the reference genome which in reality can be much larger (over 2 kb). The artificial reduction of the
reference genome means that the same signal is collapsed to a smaller length resulting in at least 2-fold signal increase over the middle of the region of
enrichment at the C-SNV element. Since the exact sequence or size of the repeat is not known in the genomes analysed, this has not been corrected for.
C Strand-specific RNA-seq of polyadenylated selected (pA+) and non-polyadenylated (pA−) RNA, read density (in RPKM) represents an average of 3
independent experiments, 3 replicates for wild type line AH017-13 or 3 clones of C-SNV iPSCs differentiated to erythroid cells. The region of the T to
C mutation is highlighted in green (SNV), gene annotation by Refseq is in blue, pseudo genes are in pink. Coordinates (hg19) chr16:209,000–217,000.
D qPCR quantification of HBA1/HBA2 in reference to RPS18 in mRNA obtained from 3 independent wild type iPSC lines (WT) or 3 iPSC clones obtained
from the same patient material (C-SNV) differentiated to erythroblasts. All lines were differentiated twice (one replicate was removed as an outlier due to
low levels): WT (n= 6) in blue, C-SNV (n= 5) in red. Violin plots display median (dotted black line) quartile lines (coloured dotted line) and individual data
points (black dots). P-values are obtained using unpaired, two-tailed student t-test.
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Fig. 2 Point mutation causes the emergence of a de novo promoter. A 138 bp unique sequence around the causative point mutation. The SNV is labelled
using the degenerate DNA symbol Y (T/C), key features are highlighted: KLF1 binding site (magenta), GATA1 (red), composite half E-box-GATA motif
(orange), core promoter element XCPE1 (blue) and TSS (black). B ChIP-qPCR for GATA1 and KLF1, sequences for TaqMan assays can be found in
Supplementary Table 1. Values represent an average of 3 independent experiments, 3 replicates for wild type iPSC line AH017-13 differentiated to
erythroblasts (in blue) or 3 C-SNV iPSC clones (in red). Error bars represent one standard deviation. P values are obtained using unpaired, two-tailed
student t-test. C Chromatin accessibility by ATAC-seq. The enhancer elements (R1–R4) are highlighted in orange, the site of the T to C mutation is
highlighted in green (SNV), gene annotation by Refseq is in blue. Read-densities represent an average of 3 independent differentiation experiments: wild
type iPSC line SB-AD2-01 (labelled WT), 3 C-SNV iPSC clones (labelled C-SNV), 4 clones of edited SB-AD2-01 cells where the T base at position 209,709
(hg19) of chr16 was changed to a C (labelled T–C), 4 clones of edited C-SNV iPS cells (line LA01) where the C base at position 209,709 (hg19) of chr16
was changed to a T (labelled C–T). Coordinates (hg19) chr16:108,000-238,000. D qPCR quantification of HBA1/HBA2 in reference to RPS18 in mRNA
obtained from independent differentiation experiments: 5 from wild type iPSC line SB-AD2-01 (WT), 3 C-SNV iPSC clones (C-SNV) differentiated to
erythroblasts twice (one replicate was removed as an outlier), 4 T–C clones (labelled T–C), 4 C–T clones (labelled C–T). WT (n= 5) in blue, C-SNV (n= 5)
in red, T–C (n= 4) in cyan, C–T (n= 4) in magenta. Violin plots display median (dashed black line) quartile lines (coloured dotted line) and individual data
points (black dots). P values are obtained using unpaired, two-tailed student t-test. E qPCR quantification of novel transcript (TaqMan assay in
Supplementary Table 1) in reference to RPS18 in mRNA obtained from independent differentiation experiments as in D). P values are obtained using
unpaired, two-tailed student t-test.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23980-6 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:3806 | https://doi.org/10.1038/s41467-021-23980-6 | www.nature.com/naturecommunications 5
expression (Fig. 4F. These observations indicate that placing the
element within the sub-TAD but outside of the region between
the enhancers and promoters does not significantly interfere with
enhancer-promoter interactions as judged by 3 C experiments.
This is in line with our recent studies showing that the extension
of the α-globin domain to encompass additional genes does not
result in promoter competition but results in the formation of a
larger chromatin hub where the extra elements together with the
native elements take part in multiway interactions without
causing major changes in α-globin expression47. Together these
findings suggest that although there may be some competition
between the newly formed promoter and the enhancers, the C-
SNV promoter may also act by blocking enhancer-promoter
interactions when placed between the α-globin enhancers and
their promoters. One caveat of this interpretation lies in the
uncertainty of whether promoter strength might determine its
ability to successfully compete with other promoters. Indeed, the
signal levels of the promoter mark H3K4me3 are much lower in
the promoter insertion lines, for this reason we returned to
examining the promoter in its native position.
The new promoter acts as orientation-dependent enhancer-



















































































































Fig. 3 New promoter sequesters interactions with the α-globin enhancers away from their cognate promoters. A Top panel shows overlaid, normalised
Capture-C data for the novel promoter (SNV Viewpoint) in erythroid cells derived from 3 independent differentiation experiments: 3 biologically
independent samples of wild type iPSC line AH017-13 (WT in blue) or 3 clones of C-SNV iPSCs obtained from the same patient material (C-SNV in red).
The mean, plus and minus one standard deviation (S.D.), of sliding 5 kb windows are visualised as a dark coloured line and a lighter coloured shadow,
respectively. Differential tracks (in dashed rectangle) show a subtraction (C-SNV minus WT) of the mean value of meaningful interactions per restriction
fragment: positive values (in black) display an increase in interaction over a region in the mutant cells (C-SNV) compared to wild type, while negative
values (in grey) indicate a decrease. The enhancer elements (R1 to R4) are highlighted in orange, the site of the T to C mutation is highlighted in green
(SNV), gene annotation by Refseq is in black (except α-globin genes in purple). Coordinates (hg19) chr16:69,200-327,999. B Data presented as in A,
viewpoint is promoters of HBA1 and HBA2. C Data presented as in A, viewpoint is enhancer R2. D ChIP-seq for CTCF, enhancer elements (R1 to R4) are
highlighted in orange, the site of the T to C mutation is highlighted in green (SNV), gene annotation by Refseq is in blue. Read-densities represent an
average of 3 independent differentiation experiments, 3 replicates for wild type iPSC line AH017-13 (WT in blue) or 3 C-SNV iPSC clones (C-SNV in red)
differentiated to erythroblasts. The third track (CTCF) displays WT and C-SNV overplayed, black indicates shared signal while red and blue indicate signal
unique for the mutant and wild type lines, respectively. Coordinates (hg19) chr16:108,000-238,000.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23980-6
6 NATURE COMMUNICATIONS |         (2021) 12:3806 | https://doi.org/10.1038/s41467-021-23980-6 | www.nature.com/naturecommunications
and enhancer in mammalian cells such as boundaries have been
shown to commonly act in an orientation dependent manner48. It
is possible that this novel element may act in a similar manner,
although we could find no evidence for orientation-specificity in
promoters that act as enhancer-blockers in Drosophila or yeast.
To test if the orientation of the C-SNV element contributes to its
ability to block enhancer-promoter interactions, we inverted the
active C-SNV promoter sequence in its natural position (Fig. 5A)
(for genome editing design and genetic screen see Supplementary
Fig. 5). Asking if the element still acted as a unidirectional pro-
moter after the inversion we showed that the inverted element is
still capable of opening chromatin, is marked by H3K4me3 and is
capable of recruiting RNAP II (Fig. 5B, C). Importantly, the
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were similar to those in the C-SNV lines, suggesting that even
when inverted promoter strength is maintained. We also proved
that the unidirectional nature of the transcriptional activity is
preserved, with transcripts with similar levels of expression now
extending towards the enhancers (Fig. 5D). To determine whether
the C-SNV promoter still blocked enhancer-promoter interac-
tions when inverted, we performed Capture-C from the α-globin
promoters and enhancer R2, and qPCR analysis for α-globin
expression. This showed that after inversion of the C-SNV pro-
moter the α-globin promoters interact more frequently with their
enhancers while the contacts between the α-globin enhancers and
the inverted C-SNV promoter decrease (Fig. 5F). Consistent with
this, the levels of α-globin mRNA return to wild type levels fol-
lowing the inversion of the C-SNV promoter (Fig. 5E). Since the
C-SNV sequence appears to act as an equally strong promoter in
either orientation, it should “compete” equally for the enhancer in
either orientation. By contrast, we have shown that the inverted
C-SNV promoter no longer causes local gene mis-regulation.
These observations support the hypothesis that the new (C-SNV)
promoter acts as an enhancer-blocker and that this effect is
constrained by its orientation in the active locus.
Discussion
In this work, we have found that a gain of function SNV causes
the emergence of an active promoter in a tissue-specific gene
locus, disrupting normal chromatin interactions and gene reg-
ulation. By changing the position and orientation of the novel
promoter, we show that rather than simply competing for the
activity of the enhancer within a defined sub-TAD, the new
promoter acts in an orientation-dependent manner. It pre-
dominantly disrupts chromatin interactions only when placed
between the enhancers and the promoters of the α-globin genes,
and only in one orientation (see Fig. 6). This raises two possi-
bilities to explain the effects of the C-SNV promoter at its natural
location between the enhancers and the α-globin promoters. One
is that the resulting reduction in α-globin expression could reflect
a role for the C-SNV element as an orientation-dependent
enhancer-blocker. Alternatively, it could be that the enhancer-
promoter interaction is weaker when the C-SNV promoter is
inverted with respect to the enhancer, with the promoter inver-
sion altering the enhancer’s ability to recognise its target. This, in
turn, might reduce the C-SNV promoter’s ability to compete for
the enhancer activity. However, there is no current evidence, to
our knowledge, to suggest that enhancers differ in their interac-
tions with respect to the orientation of their cognate promoters. If
so, this would contest the commonly held hypothesis that
enhancers and promoters interact equally regardless of their
orientation49. Of interest, we have also recently shown that the α-
globin promoters themselves may act to delimit enhancer con-
tacts within the context of the sub-TAD50. Together these
observations support the concept that promoters may act to block
enhancer-promoter interactions in mammals as in Drosophila.
However, the mechanism(s) by which a promoter may act as an
orientation dependent enhancer-blocker are not yet known. We
can only speculate that the motif grammar, the conformation of
multiprotein complexes at the promoter and/or the direction and
the act of transcription may all play a role in this. Further studies
varying these parameters will be required to determine such
mechanisms. The observation that a tissue-specific promoter can
act to block an enhancer promoter interaction in an orientation-
dependent manner raises the question of whether other pro-
moters, most notably those that are situated at the edges of self-
interacting domains, might exhibit the same type of effect and
whether their orientation might serve as an additional mechanism
that cells use to direct specificity of interactions and shape local
chromatin conformation. Finally, variants like C-SNV which
generate de novo regulatory elements can only be identified by
observation in the correct genotype or, as shown here, through
predictive machine learning approaches. These findings should
prompt others to re-evaluate SNVs lying outside of known reg-
ulatory elements when studying human traits associated with
natural variation.
Methods
Induced pluripotent stem cell maintenance. Human iPSCs were cultured at
37 °C 5% CO2 in mTeSR1 medium (StemCell Technologies) on tissue culture
treated plastic ware (Corning) coated with Human ESC Qualified Matrigel
(Corning) with daily medium changes. Cultures were passaged 1 in 8 when 70–80%
confluent using a non-enzymatic method employing a 0.02% EDTA containing
solution (Versene from Lonza). Frozen stocks were stored in 50% mTeSR1 30%
Knock-Out Serum Replacement (Gibco) 10% Knock-Out DMEM (Life Technol-
ogies) 10% DMSO (SIGMA) under liquid Nitrogen vapour. Frozen stocks were
resurrected in mTeSR1 medium containing 10 μM ROCK inhibitor (RnD).
Fig. 4 Placing the novel promoter behind the enhancers does not recapitulate the effect seen in the native position. A The active C-SNV promoter
sequence (703 bp) was placed behind the α-globin enhancers before the CTCF site delimiting the chromatin interactions within the locus. B ATAC-seq: the
enhancer elements (R1–R4) are highlighted in orange, the inserted C-SNV promoter is highlighted in green (Promoter insertion), gene annotation by Refseq
is in blue. Read-densities represent an average of 3 independent differentiation experiments for wild type iPSC line SB-AD2-01 (labelled WT), 3 clones of
edited SB-AD2-01 cells where the 703 bp of the active C-SNV promoter sequence is inserted behind R1 in the antisense orientation (labelled as Promoter
Insertion). Reads from the Promoter Insertion cells were mapped to a custom genome which contains the 703 bp promoter insertion in antisense.
Coordinates (hg19) chr16:108,000-238,000. C ChIP-seq, highlighted regions are as in a). Read-densities represent an average of 3 independent
differentiation experiments for wild type iPSC line SB-AD2-01 (in blue), 3 clones of Promoter Insertion cells (in green). The tracks are overplayed, the
darker colour indicates shared signal while green and blue indicate signal unique for the promoter insertion and wild type lines, respectively. Reads from the
Promoter Insertion cells were mapped to a custom genome. Coordinates (hg19) chr16:108,000-238,000. D Strand-specific RNA-seq of polyadenylated
selected (pA+) and non-polyadenylated (pA−) RNA, read density (in RPKM) represents an average of 3 independent differentiation experiments, 3
replicates for wild type line SB-AD2-01 (WT) or 3 clones of Promoter Insertion cells (Insert). The region of the promoter insertion is highlighted in green,
the TSS is marked by a black line, gene annotation by Refseq is in blue. Reads from the Promoter Insertion cells were mapped to a custom genome.
Coordinates (hg19) chr16:147,000-152,000. E qPCR quantification of HBA1/HBA2 in reference to RPS18 in mRNA obtained from independent differentiation
experiments: 5 from wild type iPSC line SB-AD2-01 (WT), 4 clones of T–C cells (T–C), 3 clones of Promoter Insertion cells (Promoter Insertion). WT (n=
5) in blue, T–C (n= 4) in cyan, Promoter Insertion (n= 3) in green. Violin plots display median (dashed black line) quartile lines (coloured dotted line) and
individual data points (black dots). P values are obtained using unpaired, two-tailed student t-test. F Top panel shows overlaid, normalised Capture-C data
for either the promoters of the α-globin genes (left graph) or enhancer R2 (right graph) in erythroid cells derived from 3 independent differentiation
experiments: 3 biologically independent samples of wild type iPSC line SB-AD2-01 (WT in blue) or 3 clones of Promoter Insertion cells (P-In in green). The
mean, plus and minus one standard deviation (S.D.), of sliding 5 kb windows are visualised as a dark coloured line and a lighter coloured shadow,
respectively. Differential tracks (in dashed rectangle) show a subtraction (P-In minus WT) of the mean value of meaningful interactions per restriction
fragment. Reads were mapped to the wild type genome. Coordinates (hg19) chr16:69,200-327,999.
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Wild type human induced pluripotent stem cell lines SB-AD2-01, SB-AD3-01
and AH017-13 were obtained from Oxford StemBANCC. C-SNV human induced
pluripotent stem cell lines LA01, LA06 and LA13 were generated and validated in
house. Ethical approval for the study was granted by North West Research Ethics
Committee of NHS National Research Ethics Services, Ref: MREC 03/8/097. The
experimental procedures in this study were carried out in accordance with the
approved guidelines. Informed consent was obtained for the generation of human
derived iPSC lines.
Reprogramming to pluripotency. Reprogramming EBV immortalised B-cells
from an individual homozygous the C allele (C-SNV) was performed using the
CytoTune-iPS 2.0 Sendai Reprogramming Kit (Life Technologies) according to
manufacturer’s protocol using the feeder-based reprogramming method on
Mitomycin C inactivated MEF plated dishes. When iPSC colonies were ready for
transfer (day 18–20) they were transferred onto a Matrigel coated plate in mTeSR1
medium. Subsequently, the lines were maintained for 2 months until they reached
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Fig. 5 Changing the orientation of the promoter alleviates repression and increases α-globin enhancer-promoter contacts. A The native promoter was
inverted using heterotypical loxP sites located 4011 bp upstream and 2975 bp downstream of the XCPE1 TSS (fragment chr16:205,734-212,720, hg19).
B ATAC-seq: the enhancer elements (R1 to R4) are highlighted in orange, the site of the T to C mutation is highlighted in green (SNV), the inverted region
is highlighted in light blue, gene annotation by Refseq is in blue. Read-densities represent an average of: 3 C-SNV iPSC clones (labelled C-SNV), 3 clones of
edited C-SNV cell line LA01 where the heterotypical loxP sites are inserted but the C-SNV promoter segment is not inverted (labelled nonINV), 3 clones of
edited patient line LA01 where the C-SNV promoter segment is inverted (labelled INV). Reads for C-SNV and nonINV were mapped to the normal genome,
reads for INV were mapped to a custom genome where a 7 kb segment containing the C-SNV promoter is inverted. Coordinates (hg19) chr16:108,000-
238,000. C ChIP-seq, highlighted regions are as in a). Read-densities represent an average of 2 or 3 independent differentiation experiments, 3 C-SNV
iPSC clones (C-SNV in red), 2 clones of INV cells (INV in purple). Reads for C-SNV were mapped to the normal genome, reads for INV were mapped to a
custom genome. Coordinates (hg19) chr16:108,000-238,000. D Strand-specific RNA-seq of polyadenylated selected (pA+) and non-polyadenylated
(pA-) RNA, read density (in RPKM) represents an average of 2 or 3 independent differentiation experiments: 3 C-SNV iPSC clones (C-SNV) or 2 clones of
INV cells (INV). The inverted segment is highlighted in blue, the location of the LoxP sites is marked by orange triangles, the region of the T to C mutation
is highlighted in green (SNV), gene annotation by Refseq is in blue with pseudogenes in pink. Reads for C-SNV were mapped to the normal genome, reads
for INV were mapped to a custom genome. Coordinates (hg19) chr16:202,000-217,000. E qPCR quantification of HBA1/HBA2 in reference to RPS18
in mRNA obtained from independent differentiation experiments: 3 independent wild type iPSC lines differentiated twice (WT), 3 C-SNV iPSC clones
(C-SNV) differentiated twice (one replicate removed as an outlier), 3 clones of nonINV cells (nonINV), 3 clones of INV cells (INV). WT (n= 6) in blue,
C-SNV (n= 5) in red, nonINV (n= 3) in orange, INV (n= 3) in purple. Violin plots display median (dashed black line) quartile lines (coloured dotted line)
and individual data points (black dots). P-values are obtained using unpaired, two-tailed student t-test. F Top panel shows overlaid, normalised Capture-C
data for either the promoters of the α-globin genes (left graph) or enhancer R2 (right graph) in erythroid cells derived from 3 independent differentiation
experiments: 3 C-SNV clones (C-SNV in red) or 3 clones of INV cells (INV in purple). The mean, plus and minus one standard deviation (S.D.), of sliding
5 kb windows are visualised as a dark coloured line and a lighter coloured shadow, respectively. Differential tracks (in dashed rectangle) show a subtraction
(INV minus C-SNV) of the mean value of meaningful interactions per restriction fragment. Reads were mapped to the wild type genome. Coordinates
(hg19) chr16:69,200-327,999.
































Restoration of 3C interactions
Fig. 6 C-SNV promoter behaviour in different contexts within the α-globin locus. Schematic shows the effect the active C-SNV promoter has on the
regulation of the α-globin locus when placed either in its native location (labelled C-SNV promoter in green) or inserted behind the α-globin enhancers
(labelled Promoter insertion in green). Elements of importance are highlighted on an artificially merged ATACseq track: enhancers R1-R4 in orange and
HBA2/1 genes in red. The effects of the different genomic arrangements are adjacent to the conformation of the element on the schematic.
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cryogenic store. Human iPSC lines at passage 17–20 were assessed for pluripotency
marker expression using the PSC 4-Marker Immunocytochemistry Kit (Invitrogen)
as per the manufacturer’s protocol. Copy number variation analysis was performed
on high quality genomic DNA using the Infinium HD assay on Human CytoSNP
12 Beadchip v2.1 (Illumina) at the Wellcome Trust Centre for Human Genetics
(Oxford). Data was analysed using the KaryoStudio software package (Illumina).
Genome editing of iPSCs. DNA was introduced into human iPSCs by a lipo-
fection based method using Fugene 6 (Promega). Up to 8 μg of DNA was used per
106 cells, equal amounts of single-stranded repair template DNA and pSpCas9
(BB)-2A-Puro (PX459) V2.0 plasmid DNA. For point mutation and lox site
insertion single stranded oligonucleotides were ordered from IDT. For promoter
insertion single stranded DNA was generated in house using λ exonuclease and a 5’
phosphorylated primer (for sequences see Supplementary Table 1). Exogenous
DNA containing cells were selected using puromycin for 24 h, cells were then
maintained as normal for one passage. The puromycin resistant cells were brought
to a single cell suspension using Accutase (Millipore) and seeded at low density
(~800 cells in suspension per 10cm2). After 7–9 days iPSC colonies were picked
into a 96-well plate coated with Matrigel in mTeSR1 medium with 10 μM ROCK
inhibitor. The 96 well plate was split to create 2 replica plates, one of the replica
plates was used for genotyping the other one was used to expand the clones with
correct edits.
Erythroid differentiation of iPSCs. Prior to the initiation of differentiation pro-
tocol, human iPSCs were cultured for at least 15 days on Vitronectin (Invitrogen)
coated plates (Corning; TC treated) in STEMPRO hESC media (Invitrogen) sup-
plemented with 20 ng/ml bFGF (RnD). Cultures were maintained in this way for
5–6 passages at high confluency and split 1 in 4 when over 85% confluent. Human
iPSCs were differentiated as published by Olivier et al.12 and harvested on day 21 of
the differentiation protocol. Flow cytometry analysis was performed on 2 × 105
cells resuspended in 200 μl of 2% bovine serum albumin (SIGMA) in phosphate
buffered saline and labelled for 20 min at 4 °C with 1:200 dilution of fluorescein
isothiocyanate (FITC) conjugated anti-CD71 (BD Biosciences; 555536) and 1:200
dilution of phycoerythrin (PE) conjugated anti-CD235a (BD Biosciences; 340947).
After staining cells were harvested and resuspended in PBS containing 0.02%
Hoechst 33258 pentahydrate nucleic acid stain (Invitrogen). Analysis was per-
formed on an Attune NxT Flow Cytometer (Invitrogen) and subsequently using
FlowJo software for gating on viable single cell events and representing the data as a
dot plot. Morphological analysis was preformed using a modified Wright stain on a
Hemateck 03564647 slide strainer (BAYER). The slides were then imaged on a
Nikon inverted microscope.
RNA expression analysis and TSS mapping. Total RNA was isolated from 5 ×
106 day 21 erythroid cells using the Direct-zol RNA kit (Zymo) as per manu-
facturer’s instructions. DNase I digestion was performed on column. RNA purity
was assessed using Nanodrop ND-1000 spectrophotometer (ThermoFisher Scien-
tific). RNA integrity was analysed using RNA ScreenTape Assay (Agilent). For
qRT-PCR 500 ng of DNA free RNA was reverse-transcribed using the Superscript
III First Strand Synthesis kit (Life Technologies) and the cDNA solution was
treated with RNase H according to manufacturer’s protocol. Commercially vali-
dated TaqMan assays (Applied Biosystems) were used in qRT-PCR experiments,
these can be found in Supplementary Table 1. Custom TaqMan assays were used
for detecting the novel transcript produced from the C-SNV promoter (sequences
for these are found in Supplementary Table 1). Reactions were carried out in
triplicate in 96-well plates on the StepOnePlus Real-Time PCR System (Thermo-
Fisher Scientific). Quantification of data was made using the ΔCt method to
determine the relative abundance of the gene of interest compared to a house-
keeping control RPS18. Statistical significance was determined using unpaired, two-
tailed student t-test. For RNA-seq libraries, 1 μg of total RNA was depleted of
rRNA using the rRNA Removal Kit (Illumina) according to the manufacturer’s
instructions. NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB) was used
to separate polyadenylated from non-polyadenylated RNA, subsequently strand-
specific cDNA was synthesised, and the resulting libraries prepared for Illumina
sequencing using the NEBNext Ultra II Directional RNA Library Prep Kit for
Illumina (NEB) following the manufacturer’s instructions. Polyadenylated and
non-polyadenylated RNA-seq libraries were sequenced on the NextSeq platform
using High-output 75cycle kits (Illumina), paired end sequencing. Reads were
aligned to the hg19 human genome (or custom genomes based on hg19 with
corresponding edited sequence changes) build using the STAR aligner tool (version
2.7.4) and normalised to Reads Per Kilobase per Million (RPKM). The C-SNV
promoter TSS was mapped using the FirstChoice RLM-RACE Kit (Invitrogen) with
total RNA from day 21 erythroid cells from C-SNV line LA01 following manu-
facturer’s instructions (for 5’ RACE primer see Supplementary Table 1). The
resulting PCR products were prepared for Illumina sequencing using the NEBNext
Ultra II Directional RNA Library Prep Kit for Illumina (NEB) following the
manufacturer’s instructions. Libraries were sequenced on the NextSeq platform
using High-output 75cycle kits (Illumina), paired end sequencing. Reads were
aligned to the hg19 human genome build using the bowtie 2 aligner tool (version
2.3.2 http://bowtiebio.sourceforge.net/bowtie2/index.shtml) and normalised to
Reads Per Kilobase per Million (RPKM).
ChIP-seq. Cells were fixed at 2.5 × 106 cells/ml of 10% FCS RPMI media (Gibco)
with 1% formaldehyde (SIGMA) for 10 min at RT. Fixed cells were lysed at 5 × 107
cells/ml of cell lysis buffer (5 mM PIPES (Gibco), 85 mM KCl, 0.5% NP-40
(SIGMA))+ proteinase inhibitor (PI) (ROCHE) on ice for 20 min. The lysed fixed
nuclei were lysed in nuclear lysis buffer (50 mM Tris-HCl, 10 mM EDTA (both
from Life Technologies) 1% SDS (SIGMA))+ PI at a concentration of 1 × 108 cells/
ml. The nuclear lysis was sonicated using the Covaris S220 Focused-ultrasonicator
in 130 μl microTUBEs (Covaris). The sonicated lysate was spun at max speed at
10 °C to remove insoluble material. The clear fixed chromatin was diluted 1 in 10
with RIPA buffer w/o SDS+ PI (10 mM Tris-HCl, 1 mM EDTA, 0.5 mM EGTA
(SIGMA), 1% Triton X-100 (SIGMA), 0.1% Na Deoxycholate (SIGMA), 140 mM
NaCl). The diluted chromatin was precleared twice with 10 µl of a 1:1 mix of
Protein A and Protein G Dynabeads (Invitrogen) by incubating at 4 °C for 30 mins
and discarding the beads. The pre-cleared chromatin was incubated with the
appropriate amount of antibody coupled to a 100 µl 1:1 mix of Protein A and
Protein G Dynabeads at 4 °C overnight. Chromatin bound beads were washed
twice with RIPA (10 mM Tris-HCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-
100, 0.1% SDS, 0.1% Na Deoxycholate, 140 mM NaCl) +PI, then twice with high
salt RIPA (same as RIPA but with 500 mM NaCl) +PI, once with LiCl RIPA (same
as RIPA but with 250 mM LiCl instead of NaCl) +PI and twice with TE buffer.
Chromatin was eluted off beads using 20 mM Tris-HCl, 5 mM EDTA, 50 mM
NaCl, 1% SDS, 130 µg/ml RNase A, 65 µg/ml Proteinase K. Eluted chromatin and
Input samples were incubated at 65 °C overnight to de-crosslink DNA from pro-
tein. DNA was isolated by Phenol-Cholorform (SIGMA) extraction as per man-
ufacturer’s protocol. The ChIP library preparation was performed using the
NEBNext Ultra DNA Library Preparation Kit for Illumina (NEB) as per manu-
facturer’s instructions. The libraries were sequenced on the NextSeq platform using
High-output 75cycle kits (Illumina), paired end sequencing. Data were analysed
using an in-house pipeline51. Versions of software packages used for the analysis
include FASTQC 0.11.9, Bowtie 2.3.2, Samtools 0.1.19, Bedtools 2.25.0, Deeptools
2.2.2. Briefly, reads were mapped onto human genome build hg19 or custom
genome builds based on human genome build hg19 using bowtie 2 (version 2.3.2
http://bowtiebio.sourceforge.net/bowtie2/index.shtml). PCR duplicates and ploidy
regions were removed, and biological replicates were normalised to reads per 108.
The antibodies used are: RNA Polymerase II N-20 antibody SC-899 (Santa Cruz
Biotechnology) 6 μg per 1 ml of chromatin from 1 × 107 cells; Monoclonal anti-
acetyl-Histone H3 (Lys27) antibody 17-683 (Merck Millipore) 2 μg per 1 ml of
chromatin from 1 × 107 cells; Polyclonal anti-trimethyl-Histone H3 (Lys4)
antibody 07-473 (Merck Millipore) 1 μg per 1 ml of chromatin from 1 × 107 cells;
Polyclonal anti-monomethyl-Histone H3 (Lys4) antibody ab195391 (Abcam) 4 μg
per 1 ml of chromatin from 1 × 107 cells; Polyclonal anti-GATA1 antibody ab11852
(Abcam) 8 μg per 1 ml of chromatin from 1 × 107 cells; Polyclonal anti-CTCF
antibody 07-729 (Merck Millipore) 10 μl serum per 1 ml of chromatin from 1 × 107
cells. Polyclonal anti-KLF1 antibody was kindly provided by the Perkins
Laboratory, Translational Research Institute, Brisbane, Australia (used 30 μl serum
per 1 ml of chromatin from 1 × 107 cells).
ATAC-Seq. ATAC-seq was performed as previously published52. Briefly, 7 × 104
cells per replicate were lysed and nuclei were isolated prior to tagmentation with
Tn5 transposase (Illumina) for 30 min at 37 °C. Tagmented DNA was purified
using the MinElute kit (Qiagen) and amplified using the NEBNext 2x Mastermix
(NEB) and custom barcoded primers. The libraries were sequenced on the NextSeq
platform using High-output 75cycle kits, paired end sequencing. Data were ana-
lysed using an in-house pipeline53. Briefly, reads were mapped onto human gen-
ome build hg19 or custom genome builds based on human genome build hg19
using bowtie 2 (version 2.3.2 http://bowtiebio.sourceforge.net/bowtie2/index.
shtml). PCR duplicates and ploidy regions were removed, and biological replicates
were normalised to reads per 108. Mitochondrial DNA was excluded from the
normalisation. Predicted open chromatin scores for reference and C-SNV
sequences were generated using deepHaem31 using both variant alleles with 1 kb of
flanking reference sequence.
Next generation capture C. Next generation capture C was performed as pre-
viously published41. Briefly, 1 × 107 cells per replicate were fixed in 2% for-
maldehyde. 3 C libraries were prepared following digestion with NlaIII enzyme in
CutSmart buffer (NEB). Libraries for capture were generated using the NEBNext
DNA library Prep Reagent Set (NEB) following the manufacturer’s protocol up to
the addition of adapters then the libraries were indexed using the Herculase II
Fusion Polymerase kit (Agilent) and the NEBNext Multiplex Oligos for Illumina
Primers (NEB) following the manufacturer’s protocol. Capture was performed on
pooled indexed libraries using biotinylated DNA probes (Supplementary Table 1)
and the NimbleGen SeqCap EZ Reagent kit (Roche) following manufacturers
protocol. The libraries were sequenced on the NextSeq platform using Mid-output
300 cycle kits, paired end sequencing. NG Capture-C data were analysed using the
CaptureCompendium toolkit53 with human refence genome build hg18. Reporter
counts were normalised to 105 for the calculation of the mean and standard
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23980-6 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:3806 | https://doi.org/10.1038/s41467-021-23980-6 | www.nature.com/naturecommunications 11
deviation for each replicate (n= 3). Mean reporter counts were divided into 250 bp
bins and smoothed using a 5 kb window.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support this study are available from the corresponding authors upon
reasonable request. ATAC-seq, ChIP-Seq, RNA-seq and NG Capture-C raw data and
bigwig files generated in this study are available under Gene Expression Omnibus (GEO)
accession GSE159875 Analyses and coordinates referenced here are for either the hg19,
hg18 human reference genomes, or custom genomes hg19_INV (inverted C-SNV
promoter), hg19_Vas (promoter insertion in anti-sense behind enhancers) or hg19_Vs
(promoter insertion in sense behind enhancers) based on reference human genome hg19,
as indicated in figure legends. Sequences for chromosome 16 from the custom genomes
are available in FASTA format as supplementary files in GEO Subseries GSE159871.
Figures that have associated raw data files: Fig. 1A–C); Fig. 2C); Fig. 3A–D); Fig. 4B–F);
Supplementary Fig. 4b–d). Source data are provided with this paper.
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